The involvement of In Silico Medicine in the formation of Napa Therapeutics to run drug discovery based on advances in understanding of mitochondrial metabolism in aging is an example of the premium placed on any approach that might plausibly reduce the cost and time involved in finding drug candidates. We will no doubt see a lot more of this sort of thing as computational methodologies become a plausible replacement for greater portions of the existing costly, hands-on, mechanical screening processes.
Draw a triangle in the present field of aging research with the three points set at calorie restriction mimetics, exercise mimetics, and general tinkering with energy metabolism, then efforts to increase NAD+ levels in mitochondria might be found somewhere in the midst of that space. That line of work is growing in popularity, and the early human trials of compounds like nicotinamide riboside suggest that the effect size might be worth chasing if the costs are low. (Though of course the development costs are never low for any approach that must pass through the full regulatory process).
Helping mitochondria to function more effectively in
Article originally posted at